Desvenlafaxine — $0 on Listed Strengths

Other medications in Mental Health

• Dextroamphetamine
• Disulfiram
• Duloxetine
• Escitalopram
• Esketamine Nasal
• Fluoxetine
• Fluphenazine
• Fluvoxamine

About Desvenlafaxine

Desvenlafaxine, commonly known by its brand name Pristiq, is a medication prescribed to help manage major depressive disorder. Understanding your treatment is crucial, and so is affording it. At TheDrugClub, we're dedicated to helping our members navigate the costs of essential medications like desvenlafaxine, ensuring you can access the care you need with significant savings.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Desvenlafaxine is approved for (FDA label)

Desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ]. Desvenlafaxine Extended-Release Tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: August 21, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Desvenlafaxine (FDA label)

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.1) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [see Warnings and Precautions (5.1) ] . Desvenlafaxine extended-release tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased the risk of suicidal thoughts and behaviors in children, adolescents and young adults taking antidepressants ( 5.1 ). Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Desvenlafaxine extended-release tablets are not approved for use in pediatric patients ( 8.4 ).

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Desvenlafaxine (FDA label)

25 mg Tablet: Brown colored, round shaped convex, film coated tablet debossed with "˄" on one side and plain on the other side. A41 50 mg Tablet: Pink colored, round shaped convex, film coated tablet debossed with "˄" on one side and plain on the other side. A42 100 mg Tablet: Beige colored, round shaped convex, film coated tablet debossed with "˄" on one side and plain on the other side. A43 Desvenlafaxine Extended-Release Tablets: 25 mg, 50 mg and 100 mg ( 3 ). Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Desvenlafaxine (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the label. Hypersensitivity [see Contraindications (4) ] Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients [see Warnings and Precautions (5.1) ] Serotonin Syndrome [see Warnings and Precautions (5.2) ] Elevated Blood Pressure [see Warnings and Precautions (5.3) ] Increased Risk of Bleeding [see Warnings and Precautions (5.4) ] Angle Closure Glaucoma [see Warnings and Precautions (5.5) ] Activation of Mania/Hypomania [see Warnings and Precautions (5.6) ] Discontinuation Syndrome [see Warnings and Precautions (5.7) ] Seizure [see Warnings and Precautions (5.8) ] Hyponatremia [see Warnings and Precautions (5.9) ] Interstitial Lung Disease and Eosinophilic Pneumonia [see Warnings and Precautions (5.10) ] Sexual Dysfunction [see Warnings and Precautions (5.11) ] Most common adverse reactions (incidence ≥5% and twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Desvenlafaxine (FDA label)

Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. Angioedema has been reported in patients treated with desvenlafaxine extended-release tablets [see Adverse Reactions (6.1) ] . The use of MAOIs intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome.

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Desvenlafaxine (FDA label)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue desvenlafaxine extended-release tablets and serotonergic agents and initiate supportive treatment ( 5.2 ). Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment ( 5.3 ). Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.4 ). Angle Closure Glaucoma: Avoid use of antidepressants, including desvenlafaxine extended-release tablets, in patients with untreated anatomically narrow angles treated ( 5.5 ). Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder. Caution patients about risk of activation of mania/hypomania ( 5.6 ). Discontinuation Syndrome: Taper dose when possible and monitor for discontinuation symptoms ( 5.7 ). Seizure: Can occur. Use cautiously in patients with seizure disorder ( 5.8 ).

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Desvenlafaxine (FDA label)

7.1 Drugs Having Clinically Important Interactions with Desvenlafaxine Extended-Release Tablets Table 8: Clinically Important Drug Interactions with Desvenlafaxine Extended-Release Tablets Monoamine Oxidase Inhibitors (MAOI) Clinical Impact The concomitant use of SSRIs and SNRIs including desvenlafaxine extended-release tablets with MAOIs increases the risk of serotonin syndrome. Intervention Concomitant use of desvenlafaxine extended-release tablets is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with desvenlafaxine extended-release tablets. Within 14 days of stopping an MAOI intended to treat psychiatric disorders. In a patient who is being treated with linezolid or intravenous methylene blue. [see Dosage and Administration (2.7) , Contraindications (4) and Warnings and Precautions (5.2) ]. Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact Concomitant use of desvenlafaxine extended-release tablets with other serotonergic drugs increases the risk of serotonin syndrome.

Source: FDA prescribing information (DailyMed). Set ID: ff837eb1-24c3-4c63-9b4b-c6b5935a9b47. SPL document ID: 598c3727-16e5-a206-e063-6294a90aadc9. Label effective date: August 21, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.